FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3193141331> ?p ?o ?g. }

• W3193141331 endingPage "6652" @default.
• W3193141331 startingPage "6642" @default.
• W3193141331 abstract "We evaluated the arginine-depleting enzyme pegargiminase (ADI-PEG20; ADI) with pemetrexed (Pem) and cisplatin (Cis) (ADIPemCis) in ASS1-deficient non-squamous non-small cell lung cancer (NSCLC) via a phase 1 dose-expansion trial with exploratory biomarker analysis.Sixty-seven chemonaïve patients with advanced non-squamous NSCLC were screened, enrolling 21 ASS1-deficient subjects from March 2015 to July 2017 onto weekly pegargiminase (36 mg/m2 ) with Pem (500 mg/m2 ) and Cis (75 mg/m2 ), every 3 weeks (four cycles maximum), with maintenance Pem or pegargiminase. Safety, pharmacodynamics, immunogenicity, and efficacy were determined; molecular biomarkers were annotated by next-generation sequencing and PD-L1 immunohistochemistry.ADIPemCis was well-tolerated. Plasma arginine and citrulline were differentially modulated; pegargiminase antibodies plateaued by week 10. The disease control rate was 85.7% (n = 18/21; 95% CI 63.7%-97%), with a partial response rate of 47.6% (n = 10/21; 95% CI 25.7%-70.2%). The median progression-free and overall survivals were 4.2 (95% CI 2.9-4.8) and 7.2 (95% CI 5.1-18.4) months, respectively. Two PD-L1-expressing (≥1%) patients are alive following subsequent pembrolizumab immunotherapy (9.5%). Tumoral ASS1 deficiency enriched for p53 (64.7%) mutations, and numerically worse median overall survival as compared to ASS1-proficient disease (10.2 months; n = 29). There was no apparent increase in KRAS mutations (35.3%) and PD-L1 (<1%) expression (55.6%). Re-expression of tumoral ASS1 was detected in one patient at progression (n = 1/3).ADIPemCis was safe and highly active in patients with ASS1-deficient non-squamous NSCLC, however, survival was poor overall. ASS1 loss was co-associated with p53 mutations. Therapies incorporating pegargiminase merit further evaluation in ASS1-deficient and treatment-refractory NSCLC." @default.
• W3193141331 created "2021-08-16" @default.
• W3193141331 creator A5000557436 @default.
• W3193141331 creator A5001102824 @default.
• W3193141331 creator A5006628495 @default.
• W3193141331 creator A5007613910 @default.
• W3193141331 creator A5007808102 @default.
• W3193141331 creator A5014243045 @default.
• W3193141331 creator A5016567170 @default.
• W3193141331 creator A5022032908 @default.
• W3193141331 creator A5028665323 @default.
• W3193141331 creator A5034514799 @default.
• W3193141331 creator A5043396792 @default.
• W3193141331 creator A5049948035 @default.
• W3193141331 creator A5058782121 @default.
• W3193141331 creator A5060844577 @default.
• W3193141331 creator A5065435228 @default.
• W3193141331 creator A5076824581 @default.
• W3193141331 creator A5079505616 @default.
• W3193141331 creator A5089578927 @default.
• W3193141331 date "2021-08-12" @default.
• W3193141331 modified "2023-10-15" @default.
• W3193141331 title "Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer" @default.
• W3193141331 cites W1126567730 @default.
• W3193141331 cites W1966242225 @default.
• W3193141331 cites W2027449497 @default.
• W3193141331 cites W2036607853 @default.
• W3193141331 cites W2070436739 @default.
• W3193141331 cites W2071146934 @default.
• W3193141331 cites W2099725888 @default.
• W3193141331 cites W2106712645 @default.
• W3193141331 cites W2119785831 @default.
• W3193141331 cites W2129920232 @default.
• W3193141331 cites W2134972696 @default.
• W3193141331 cites W2135163858 @default.
• W3193141331 cites W2152021740 @default.
• W3193141331 cites W2154260730 @default.
• W3193141331 cites W2166630497 @default.
• W3193141331 cites W2180481128 @default.
• W3193141331 cites W2291531085 @default.
• W3193141331 cites W2327358714 @default.
• W3193141331 cites W2512678052 @default.
• W3193141331 cites W2524082038 @default.
• W3193141331 cites W2527905628 @default.
• W3193141331 cites W2567746986 @default.
• W3193141331 cites W2587931206 @default.
• W3193141331 cites W2604413507 @default.
• W3193141331 cites W2609015711 @default.
• W3193141331 cites W2615791680 @default.
• W3193141331 cites W2736678913 @default.
• W3193141331 cites W2748959367 @default.
• W3193141331 cites W2790858216 @default.
• W3193141331 cites W2796582438 @default.
• W3193141331 cites W2804812017 @default.
• W3193141331 cites W2805354595 @default.
• W3193141331 cites W2887301398 @default.
• W3193141331 cites W2889366471 @default.
• W3193141331 cites W2889646458 @default.
• W3193141331 cites W2892293198 @default.
• W3193141331 cites W2901014197 @default.
• W3193141331 cites W2916469804 @default.
• W3193141331 cites W2943618951 @default.
• W3193141331 cites W2946452125 @default.
• W3193141331 cites W2949244813 @default.
• W3193141331 cites W2964649258 @default.
• W3193141331 cites W2967210753 @default.
• W3193141331 cites W2971041600 @default.
• W3193141331 cites W3012212683 @default.
• W3193141331 cites W3012408003 @default.
• W3193141331 cites W3016765594 @default.
• W3193141331 cites W3035177263 @default.
• W3193141331 cites W3083074964 @default.
• W3193141331 cites W3083661804 @default.
• W3193141331 cites W3091399767 @default.
• W3193141331 cites W3096912123 @default.
• W3193141331 cites W3182915680 @default.
• W3193141331 cites W3193141331 @default.
• W3193141331 cites W3217485783 @default.
• W3193141331 doi "https://doi.org/10.1002/cam4.4196" @default.
• W3193141331 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8495293" @default.
• W3193141331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34382365" @default.
• W3193141331 hasPublicationYear "2021" @default.
• W3193141331 type Work @default.
• W3193141331 sameAs 3193141331 @default.
• W3193141331 citedByCount "9" @default.
• W3193141331 countsByYear W31931413312021 @default.
• W3193141331 countsByYear W31931413312022 @default.
• W3193141331 countsByYear W31931413312023 @default.
• W3193141331 crossrefType "journal-article" @default.
• W3193141331 hasAuthorship W3193141331A5000557436 @default.
• W3193141331 hasAuthorship W3193141331A5001102824 @default.
• W3193141331 hasAuthorship W3193141331A5006628495 @default.
• W3193141331 hasAuthorship W3193141331A5007613910 @default.
• W3193141331 hasAuthorship W3193141331A5007808102 @default.
• W3193141331 hasAuthorship W3193141331A5014243045 @default.
• W3193141331 hasAuthorship W3193141331A5016567170 @default.
• W3193141331 hasAuthorship W3193141331A5022032908 @default.
• W3193141331 hasAuthorship W3193141331A5028665323 @default.

• next